Antagonists of Growth Hormone-Releasing Hormone in Oncology

Author(s): Andrew V. Schally, Jozsef L. Varga.

Journal Name: Combinatorial Chemistry & High Throughput Screening

Volume 9 , Issue 3 , 2006

Submit Manuscript
Submit Proposal

Abstract:

The development of antagonists of growth hormone (GH) - releasing hormone (GH-RH) is reviewed. GH-RH antagonists bind with a high affinity to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The main applications of GH-RH antagonists would be for tumor therapy. The antitumor effects of GH-RH antagonists are exerted in part indirectly through the inhibition of the secretion of pituitary GH and the reduction in the levels of hepatic insulin like growth factor (IGF-I). However, principal effects of the GH-RH antagonists are exerted directly on tumors. Antagonists of GH-RH inhibit the proliferation of various cancer cell lines in vitro and suppress in vivo the levels and the expression of mRNA for IGF-I and IGF-II in tumors. In many human cancers, the effects of GH-RH antagonists appear to be due to the blockade of the action of tumoral GH-RH. GH-RH ligand is present in various human cancers indicating that it may be an autocrine/paracrine growth factor. Splice variants (SVs) of GH-RH receptors and pituitary type of GH-RH receptors that might mediate effects of tumoral GH-RH and of GH-RH antagonists were demonstrated in many human cancers. This suggests the presence of a stimulatory loop based on GH-RH and SVs or pituitary type of GHRH receptors in diverse tumors. It was shown that GH-RH antagonists inhibited the growth of various human cancer lines xenografted into nude mice including mammary, ovarian, endometrial and prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, renal, pancreatic, gastric and colorectal carcinomas, malignant gliomas, osteosarcomas and Non- Hodgkins lymphomas. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.

Keywords: GH-RH, GH-RH receptors, receptor splice variants, inhibition of pituitary GH release, antitumor activity, cancer therapy

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 9
ISSUE: 3
Year: 2006
Page: [163 - 170]
Pages: 8
DOI: 10.2174/138620706776055449
Price: $58

Article Metrics

PDF: 3